Over the last two-and-a-half decades, MDMX has been developed from the status of the little brother of its well-studied and important “older” relative MDM2 to another key negative regulator of p53 in embryonic and, perhaps most importantly, cancer cells. This evidence concerns the gene MDM2 and cancer.